Private Healthcare Australia grants reimbursement code to IDEV’s SUPERA stent

IDEV Technologies, Inc. (IDEV), an emerging global innovator in peripheral devices, today announced that Private Healthcare Australia has granted the Company a reimbursement code for the SUPERA^® stent.  The August 2012 Prostheses List was effective August 30, 2012.  This is an important milestone as the Company continues to build a solid foundation in the Asia Pacific region. 

"Gaining the private reimbursement code opens a significant portion of the Australian market to this exciting technology," commented Trent Reutiman, IDEV's Vice President of Global Commercial Operations.  "Working closely with our distributor in Australia and New Zealand, Device Technologies, we will be able to move quickly to provide the SUPERA stent to physicians who have been awaiting reimbursement."

"This is critically important as we implement our long term strategy in the Asia Pacific region, one of the fastest growing global markets. We are pleased that Private Healthcare Australia has recognized the benefits of our technology by granting the reimbursement codes," said Christopher Owens, President and CEO of IDEV. 

In the past eighteen months the Company has initiated sales, marketing, and regulatory activities in multiple countries in the region, including the initiation of product registrations in Japan and China, as well as increased sales activities in Hong Kong and countries of the ASEAN (Association of South-East Asian Nations) region.

The SUPERA stent was designed and engineered to mimic the structure and function of vascular anatomy.  Clinical evidence demonstrates that SUPERA is the most fracture resistant stent available, with excellent outcomes even in challenging anatomical areas.

SOURCE IDEV Technologies, Inc.